Q3 2025 EPS misses consensus due to a $950M charge for policyholder credits in Florida. Strong premium growth continues.
Progressive Corporation is hitting some financial turbulence as heightened competition and rising costs take a bite out of ...
Barclays upgraded KLA Corporation (KLAC) to Overweight, hiking the price target to $1,200. The analyst cited KLA’s leadership in AI and low China risk.
Vertex Pharmaceuticals recently hit a significant milestone with its therapy, povetacicept, receiving FDA Breakthrough ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback